TN16 108919 HE 20x  TN16 108919 HE 40x 
 Figure 1. H&E, 10x. Figure 2. H&E, 20x.
TN16 108919 HE 60x  TN16 108919 E cadherin 40x 
Figure 3. H&E, 40x.  Figure 4. Loss of E-cadherin expression in invasive component (20x).
 TN16 108919 AR IHC 10x  
Figure 5. The cancer cells were diffusely positive for androgen receptor (AR), 10x.